Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

周二，H.C. Wainwright分析师Douglas Tsao将市值约6000万美元的小型生物科技公司Outlook Therapeutics Inc. (NASDAQ: OTLK ...

In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Outlook Therapeutics (OTLK) to $3 from $30 and keeps a Buy rating on ...

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...

Outlook Therapeutics, Inc. has announced the appointment of Faisal G. Sukhtian as Chairman of the Board of Directors, taking over from Randy Thurman, who will remain as Lead Independent Director.

Outlook Therapeutics, Inc. announced that it is on track for the resubmission of its Biologics License Application (BLA) for ONS-5010 (LYTENAVA™) in the first quarter of 2025, aiming for initial ...

ISELIN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein now ...